HIF1A and melanoma: In a highly hypoxic and PD-1-resistant B16-F10 melanoma mouse model (24, 25), we recently reported that inhibiting hypoxia by preventing HIF-1α/β heterodimerization in a mouse melanoma model drives immune cells into the tumor microenvironment and improves anti-PD-1- and vaccine-based immunotherapies (26).